FISH for TEL/AML t(12;21)

The FISH test for TEL/AML t(12;21) is done to confirm the diagnosis of ALL, particularly in children, and to guide the choice of treatment. It helps in identifying patients who may respond to specific therapies targeting the abnormal protein produced by the TEL-AML1 fusion gene.

A positive result for the TEL/AML t(12;21) FISH test indicates the presence of the TEL-AML1 fusion gene and suggests a diagnosis of acute lymphoblastic leukemia. This information is vital for healthcare professionals in deciding the best treatment strategy.

The sample required for the FISH test can be a blood sample or a bone marrow aspirate. A healthcare professional will draw blood from a vein, usually in the arm, or perform a bone marrow aspiration, usually from the hip bone.

The common symptoms of ALL include fatigue, fever, easy bruising or bleeding, frequent infections, bone pain, weight loss, and swollen lymph nodes.

Treatment for ALL typically involves chemotherapy to kill cancer cells. In some cases, targeted therapy, radiation therapy, and stem cell transplants may also be used.

No, the TEL/AML t(12;21) translocation is not hereditary. It is believed to occur spontaneously and is not passed down from parents to children.

There is minimal risk involved in drawing blood for the FISH test. If a bone marrow sample is needed, there might be discomfort and a small risk of infection or bleeding at the site where the sample is taken.

Patients with ALL who have the TEL-AML t(12;21) translocation often have a more favorable prognosis compared to some other genetic types of ALL. However, the outcome can vary depending on various factors, including response to treatment.

Yes, ALL can be cured in many cases, especially in children. The success of treatment depends on various factors, including the type of ALL, the patient’s age and health, and how well the leukemia responds to treatment.

The quality of the sample and technical issues with the FISH procedure can affect the test results. Therefore, it is crucial to have the test performed in a specialized laboratory.

If you are diagnosed with ALL, it is essential to discuss treatment options with your doctor. Your doctor will provide information on the best treatment approach, and it’s important to follow the treatment plan closely.

There are no known ways to prevent ALL as the exact causes are not clear. However, living a healthy lifestyle and avoiding exposure to known carcinogens can reduce the risk of developing various types of cancers.

While the TEL/AML t(12;21) translocation is most commonly associated with childhood ALL, it can also occur in adults, though less frequently.

Follow-up care is essential for monitoring the effectiveness of treatment, managing side effects, and checking for any signs of relapse. Regular check-ups with your doctor are necessary for optimal management of ALL.

FISH for TEL/AML t(12;21) is a vital diagnostic test for detecting the genetic abnormality commonly associated with acute lymphoblastic leukemia. This information is not only essential for confirming the diagnosis but also for guiding treatment decisions. Patients diagnosed with ALL should engage with their doctor in understanding their specific case and making informed decisions regarding treatment and management.